Posts
High potency active pharmaceutical ingredients are molecules
widely used in the production of hormonal drugs which are used for the
treatment of breast cancer. It is also used in the central nervous system
drugs, cardiovascular drugs, and musculoskeletal drugs. Moreover, recently they
have been also gaining demand in the gynecology & cosmetics industry. These
drugs are segmented into innovative and generic.
The growing prevalence of cancer is predominantly fueling the
market growth of the high potency active pharmaceutical ingredients. The
increasing number of the pharmaceutical industry coupled with the growing
investment in the research and development activities conducted by the
pharmaceutical industry is again contributing to the market growth. Moreover, increasing
use of high potency active pharmaceutical ingredients as antibody-drug
conjugates as it is one of the most important and effective treatments for
cancer is also projected to augment the market growth. It is also used to treat
glaucoma which is further anticipated to foster the market growth of the high
potency active pharmaceutical ingredients.
From the geographical point of view, North America is expected to
gain significant growth over the forecast period and this is attributed to the
high prevalence of the chronic disease in the region. According to the National
Health Council, chronic diseases affect around 133 million Americans,
representing more than 40% of the total population of this country. About half
of all adults have a chronic condition, and approximately 8 percent of children
ages 5 to 17 were reported by their parents to have limited activities due to
at least one chronic disease or disability.
Key Developments:
In September 2020, Seqens, a worldwide manufacturer of
pharmaceutical ingredients, has launched a specialized production unit at its
site in Villeneuve-La-Garenne, France. The $ 35 million (€ 30 million) facility
will tackle the development and production of high potency active
pharmaceutical ingredients (HPAPI).
In February 2020, Sanofi announced its plans to create a major
European company dedicated to the production and marketing to third parties of
active pharmaceutical ingredients (API), which are the essential molecules
responsible for the beneficial effects used in the composition of any drug.
In June 2019, Lonza has invested in two multi-purpose production
lines for HPAPI manufacturing at its Visp site in Switzerland. Lonza has also
optimised capacity to improve its flexibility in existing production lines,
supporting shorter time-to-market and accelerated approval timelines for
partners.
No comments:
Post a Comment